NASDAQ (usa) |
![]() |
6715.56 | -12.11 | -0.18% |
FTSE 100 (london) |
![]() |
7487.96 | -5.12 | -0.07% |
DAX (german) |
![]() |
13465.51 | 235.94 | 1.78% |
NIKKEI 225 (japan) |
![]() |
22420.08 | 408.47 | 1.86% |
Hang - Seng (hong kong) |
![]() |
28594.06 | 348.52 | 1.23% |
NIFTY - 50 (india) | ||||
Straits Times (singapore) |
![]() |
3391.61 | 17.53 | 0.52% |
KOSPI (korea) |
![]() |
2556.47 | 33.04 | 1.31% |
All Ordinaries (australia) |
![]() |
6005.30 | 28.90 | 0.48% |
BOVESPA (brazil) |
![]() |
74092.76 | -215.73 | -0.29% |
Xenetic Biosciences Inc (NASDAQ: XBIOW)
XBIOW Technical Analysis
4
As on 18th May 2022 XBIOW Share Price closed @ 1.00 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 2.05 & Sell for SHORT-TERM with Stoploss of 1.73 we also expect STOCK to react on Following IMPORTANT LEVELS. |
XBIOW Share Price
Open | 1.00 | Change | Price | % |
High | 1.00 | 1 Day | 0.00 | 0.00 |
Low | 1.00 | 1 Week | 0.00 | 0.00 |
Close | 1.00 | 1 Month | 0.00 | 0.00 |
Volume | N/A | 1 Year | 0.59 | 143.90 |
52 Week High 5.85 | 52 Week Low 0.41 |
NASDAQ USA Most Active Stocks
AMD | 96.28 | -6.04% |
AAPL | 140.82 | -5.64% |
BRQS | 0.19 | 11.76% |
SNDL | 0.41 | -6.82% |
GNUS | 0.78 | 13.04% |
AGRI | 2.92 | 8.96% |
BBIG | 3.05 | 6.64% |
ENDP | 0.62 | -46.55% |
NVDA | 169.38 | -6.82% |
SOFI | 7.23 | 2.55% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
XBIOW Daily Charts |
XBIOW Intraday Charts |
Whats New @ Bazaartrend |
XBIOW Free Analysis |
|
XBIOW Important Levels Intraday
RESISTANCE | 1.00 |
RESISTANCE | 1.00 |
RESISTANCE | 1.00 |
RESISTANCE | 1.00 |
RESISTANCE | 1.00 |
RESISTANCE | 1.00 |
RESISTANCE | 1.00 |
RESISTANCE | 1.00 |
XBIOW Target for Month May
4th UP TARGET | 5.97 |
3rd UP TARGET | 4.38 |
2nd UP TARGET | 3.39 |
1st UP TARGET | 2.41 |
1st DOWN TARGET | -0.41 |
2nd DOWN TARGET | -1.39 |
3rd DOWN TARGET | -2.38 |
4th DOWN TARGET | -3.97 |
XBIOW Weekly Target
4th UP TARGET | 4.47 |
3rd UP TARGET | 3.36 |
2nd UP TARGET | 2.67 |
1st UP TARGET | 1.98 |
1st DOWN TARGET | 0.02 |
2nd DOWN TARGET | -0.67 |
3rd DOWN TARGET | -1.36 |
4th DOWN TARGET | -2.47 |
XBIOW Target for Year 2022
4th UP TARGET | 12.02 |
3rd UP TARGET | 8.49 |
2nd UP TARGET | 6.3 |
1st UP TARGET | 4.12 |
1st DOWN TARGET | -2.12 |
2nd DOWN TARGET | -4.3 |
3rd DOWN TARGET | -6.49 |
4th DOWN TARGET | -10.02 |
Xenetic Biosciences Inc ( NASDAQ USA Symbol : XBIOW )
Sector : Other And Other Stocks in Same Sector
Sector : Other And Other Stocks in Same Sector
XBIOW Other Details
Segment | EQ | |
Market Capital | 0.00 | |
Sector | Other | |
Industry | Other | |
Offical website | > echo $website ; ?> |
XBIOW Address
![]() |
XBIOW Latest News
XBIOW Business Profile
Xenetic Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, research, and development of next-generation biologic drugs and novel orphan oncology therapeutics. The company's lead investigational product candidate is oncology therapeutic XBIO-101 (sodium cridanimod) for the treatment of progestin resistant endometrial cancer. It is also developing ErepoXen, a drug using PolyXen platform technology for the treatment of anemia in chronic kidney disease patients. The company has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts. Address:
© 2005-2021 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service